228 related articles for article (PubMed ID: 3315684)
1. Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol.
Tikkanen MJ; Helve E; Nikkilä EA
Eur Heart J; 1987 Aug; 8 Suppl E():97-101. PubMed ID: 3315684
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein fractions and receptors: a role for probucol?
Bilheimer DW
Am J Cardiol; 1986 Jun; 57(16):7H-15H. PubMed ID: 3637051
[TBL] [Abstract][Full Text] [Related]
3. Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis.
Glueck CJ
Ann Intern Med; 1982 Apr; 96(4):475-82. PubMed ID: 7039445
[TBL] [Abstract][Full Text] [Related]
4. The effects of probucol on plasma lipoproteins in polygenic and familial hypercholesterolaemia.
Cortese C; Marenah CB; Miller NE; Lewis B
Atherosclerosis; 1982 Sep; 44(3):319-25. PubMed ID: 7150396
[TBL] [Abstract][Full Text] [Related]
5. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.
Buckley MM; Goa KL; Price AH; Brogden RN
Drugs; 1989 Jun; 37(6):761-800. PubMed ID: 2667936
[TBL] [Abstract][Full Text] [Related]
6. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
Illingworth DR; Bacon S
Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
[TBL] [Abstract][Full Text] [Related]
7. Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles.
Helve E; Tikkanen MJ
Atherosclerosis; 1988 Aug; 72(2-3):189-97. PubMed ID: 3063268
[TBL] [Abstract][Full Text] [Related]
8. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
Matsuzawa Y; Yamashita S; Funahashi T; Yamamoto A; Tarui S
Am J Cardiol; 1988 Jul; 62(3):66B-72B. PubMed ID: 3394656
[TBL] [Abstract][Full Text] [Related]
9. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
Witztum JL; Simmons D; Steinberg D; Beltz WF; Weinreb R; Young SG; Lester P; Kelly N; Juliano J
Circulation; 1989 Jan; 79(1):16-28. PubMed ID: 2642754
[TBL] [Abstract][Full Text] [Related]
10. Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II).
Pietro DA; Alexander S; Mantell G; Staggers JE; Cook TJ
Am J Cardiol; 1989 Mar; 63(11):682-6. PubMed ID: 2646895
[TBL] [Abstract][Full Text] [Related]
11. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia.
Jones DB; Simpson HC; Slaughter P; Lousley S; Carter RD; Cobbe SM; Mann JI
Atherosclerosis; 1984 Oct; 53(1):1-7. PubMed ID: 6388586
[TBL] [Abstract][Full Text] [Related]
12. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Lankin VZ; Tikhaze AK; Kukharchuk VV; Konovalova GG; Pisarenko OI; Kaminnyi AI; Shumaev KB; Belenkov YN
Mol Cell Biochem; 2003 Jul; 249(1-2):129-40. PubMed ID: 12956408
[TBL] [Abstract][Full Text] [Related]
13. Effect of probucol treatment on lipoprotein cholesterol and drug levels in blood and lipoproteins in familial hypercholesterolemia.
Fellin R; Gasparotto A; Valerio G; Baiocchi MR; Padrini R; Lamon S; Vitale E; Baggio G; Crepaldi G
Atherosclerosis; 1986 Jan; 59(1):47-56. PubMed ID: 3081013
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia.
Durrington PN; Miller JP
Atherosclerosis; 1985 May; 55(2):187-94. PubMed ID: 3890872
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.
Todd PA; Goa KL
Drugs; 1990 Oct; 40(4):583-607. PubMed ID: 2083515
[TBL] [Abstract][Full Text] [Related]
16. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Plosker GL; Dunn CI; Figgitt DP
Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
[TBL] [Abstract][Full Text] [Related]
17. Treatment of homozygous familial hypercholesterolaemia with probucol.
Baker SG; Joffe BI; Mendelsohn D; Seftel HC
S Afr Med J; 1982 Jul; 62(1):7-11. PubMed ID: 7089781
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
Sasaki S; Nakagawa M; Nakata T; Endo N; Miyao K; Kitamura K; Fukuyama M; Kitani T; Yamada C
Cardiology; 1997; 88(2):160-5. PubMed ID: 9096917
[TBL] [Abstract][Full Text] [Related]
19. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
Leitersdorf E; Eisenberg S; Eliav O; Friedlander Y; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Wurm M
Circulation; 1993 Apr; 87(4 Suppl):III35-44. PubMed ID: 8462179
[TBL] [Abstract][Full Text] [Related]
20. Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia.
Mellies MJ; Gartside PS; Glatfelter L; Vink P; Guy G; Schonfeld G; Glueck CJ
Metabolism; 1980 Oct; 29(10):956-64. PubMed ID: 6999291
[No Abstract] [Full Text] [Related]
[Next] [New Search]
